| abstract |
A method of treating cancer is disclosed, the method comprising simultaneous or sequential administration of an oncolytic herpes simplex virus and a receptor tyrosine kinase (RTK) inhibitor, wherein the RTK inhibitor is an inhibitor of at least one of a vascular endothelial growth factor receptor (VEGFR) and/or a platelet derived growth factor receptor (PDGFR) and/or c-KIT (CD1 17) and/or c- MET, and wherein the combination of oncolytic herpes simplex virus and RTK inhibitor induces apoptosis in cells of the cancer. The RTK inhibitor may be an inhibitor of vascular endothelial growth factor (VEGFR), platelet derived growth factor receptor (PDGFR), c_KIT (CD117) and/or c-MET. The RTK inhibitor may be Sorafenib, Pazopanib, Cabozantinib, Sunitinib, Crizitonib or Regorafenib amongst others. The HSV may be a mutant of HSV-1in particular HSV1716 where the ICP34.5 gene does not express a functional gene product. |